Rubin Amir Dan 4

Accession 0001562180-22-007116

CIK 0001404123other

View on SEC.gov Company Profile

Filed

Oct 5, 8:00 PM ET

Accepted

Oct 6, 9:08 PM ET

Size

32.5 KB

Accession

0001562180-22-007116

Insider Transaction Report

Form 4

Period: 2022-10-04

1Life Healthcare IncONEM

Rubin Amir Dan

DirectorChair, CEO and President

Transactions

Exercise/Conversion
Common Stock
2022-10-04$4.01/sh+1,589,798$6,375,090→ 1,689,546 total
Sale
Common Stock
2022-10-04$17.17/sh−1,613,937$27,714,849→ 99,748 total
Sale
Common Stock
2022-10-04$17.18/sh−124,688$2,141,691→ 124,689 total(indirect: By Trust)
Exercise/Conversion
Stock Option (Right to Buy)
2022-10-04−1,589,798→ 0 total
Exercise: $4.01Exp: 2027-09-13→ Common Stock (1,589,798 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2022-10-04−24,139→ 5,077,573 total
Exercise: $4.01Exp: 2027-09-13→ Common Stock (24,139 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2022-10-05−2,123,402→ 2,954,171 total
Exercise: $4.01Exp: 2027-09-13→ Common Stock (2,123,402 underlying)
Exercise/Conversion
Stock Options (Right to buy)
2022-10-06−1,825,289→ 1,128,882 total
Exercise: $4.01Exp: 2027-09-13→ Common Stock (1,825,289 underlying)
Exercise/Conversion
Common Stock
2022-10-05$4.01/sh+2,123,402$8,514,842→ 2,223,150 total
Exercise/Conversion
Common Stock
2022-10-04$4.01/sh+24,139$96,797→ 1,713,685 total
Sale
Common Stock
2022-10-05$17.09/sh−2,123,402$36,298,071→ 99,748 total
Exercise/Conversion
Common Stock
2022-10-06$4.01/sh+1,825,289$7,319,409→ 1,925,037 total
Sale
Common Stock
2022-10-06$17.08/sh−1,825,289$31,181,960→ 99,748 total
Sale
Common Stock
2022-10-04$17.18/sh−124,689$2,141,683→ 0 total(indirect: By Trust)

Footnotes (8)

[F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan and were conducted by the reporting person for tax and estate planning purposes. The reporting person has adopted Rule 10b5-1 plans in the past and has adopted this Rule 10b5-1 plan in the ordinary course. The trading plans and their parameters do not reflect the reporting person's views on the closing of the pending, previously announced, merger or the prospects of the Company's business after the closing.
[F2]This transaction was executed in multiple trades at prices ranging from $17.08 to $17.225. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
[F3]This transaction was executed in multiple trades at prices ranging from $17.07 to $17.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
[F4]This transaction was executed in multiple trades at prices ranging from $17.04 to $17.135. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
[F5]This transaction was executed in multiple trades at prices ranging from $17.095 to $17.25. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
[F6]This transaction was executed in multiple trades at prices ranging from $17.09 to $17.25. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
[F7]The shares subject to the option vested upon the execution of the underwriting agreement in connection with the Issuer's initial public offering.
[F8]The shares subject to the option vest as follows: 20% of the shares subject to the option vest on the first anniversary of the vesting commencement date; and 1/60th of the shares subject to the option vest monthly thereafter over the following four years, subject to reporting person's continuous service as of each such date.

Documents

2 files

Issuer

1Life Healthcare Inc

CIK 0001404123

→

Entity typeother

Related Parties

filerCIK 0001642829

Filing Metadata

Form type: 4
Filed: Oct 5, 8:00 PM ET
Accepted: Oct 6, 9:08 PM ET
Size: 32.5 KB

View on SEC.gov